SLC29A1 and pancreatic neoplasm: Moreover, we propose the zidovudine and gemcitabine co-treatment may be a novel therapeutic strategy for pancreatic cancer by targeting the gemcitabine-induced EMT-like phenotype and suppression of hENT1 expression.